Researchers from Assembly Biosciences Inc. recently presented details on the discovery and preclinical evaluation of a novel small-molecule hepatitis B virus (HBV) and hepatitis D virus (HDV) entry inhibitor, AB-1659.
Complementarity-determining regions (CDRs) are relatively short peptide loops in antibodies where they bind to their specific antigens. Bovines, unlike humans and other vertebrates, rely on ultralong CDR H3 antibody knob regions to neutralize cryptic viral epitopes.
Assembly Biosciences Inc. has selected ABI-6250, an orally bioavailable small-molecule entry inhibitor, as a development candidate to progress to IND-enabling studies for the treatment of chronic hepatitis D virus (HDV) infection.
Tuberculosis (TB) is the second leading infectious disease killer. According to the World Health Organization, every year, more than 10 million people fall ill with TB, and 1.5 million people die from the disease. The thing is, though, that it could be worse. Not nearly everyone who is infected has TB disease. “Tuberculosis is a disease that targets a small number of infected people,” Igor Kramnik, of Boston University, told BioWorld.
Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success.
Researchers from Longhorn Vaccines & Diagnostics LLC recently presented preclinical data for the novel unconjugated peptide vaccine LHNVD-201, which is being developed as a universal vaccine candidate for protection against different strains of influenza and COVID-19.
Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success. Their work together for decades was essential to achieving mRNA vaccines, and their perseverance was rewarded today with the 2023 Nobel Prize in Medicine.
Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.
Research at Baruch S Blumberg Institute has led to the discovery of new diazepine derivatives targeting yellow fever virus nonstructural protein 4B (NS4B) for the treatment of yellow fever virus infections.
RSS
